💊 Oral delivery is preferred by patients due to its convenience and growing potential in the market, expected to grow 35% annually.
🔧 The smart capsules utilize advanced technology for targeted delivery, crucial for addressing bioavailability challenges.
🌍 Lonza’s new offerings will support innovative drug delivery solutions tailored to specific needs, enhancing healthcare outcomes.
Introduction:
Lonza has announced the expansion of its service offerings to better support the development and manufacturing needs of companies focused on smart capsules for the oral delivery of biologic therapies. This highlights the growing interest in oral administration of active pharmaceutical ingredients (APIs) and the unique challenges associated with delivering biologics through this route.
- Oral delivery is the preferred route for patients, improving adherence and accessibility to medications, with the oral biologics market projected to grow significantly.
- Smart capsules are designed to enhance precision and control in drug delivery, presenting innovative applications in various therapeutic areas including diabetes and obesity.
- Lonza’s expanded services include bespoke development and manufacturing tailored to the specific requirements of smart capsule developers.
- The offerings leverage advanced technologies such as bi-layer manufacturing for targeted release of APIs, emphasizing customization in size, design, and functionality.
- The service expansion is part of Lonza’s Innovaform™ Accelerator initiative, aimed at supporting innovation in biologic therapies.
Conclusion:
Lonza’s initiative to enhance support for smart capsule development not only addresses current challenges in oral biologic therapies but also positions the company prominently within a rapidly expanding market. The focus on tailored solutions and innovative manufacturing techniques reflects the company’s commitment to advancing healthcare delivery and addressing the unique needs of drug developers.
